key: cord-0991451-w7d37nu9 authors: Kumar, Nagi B. title: Does COVID‐19‐related cachexia mimic cancer‐related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management date: 2021-02-07 journal: J Cachexia Sarcopenia Muscle DOI: 10.1002/jcsm.12681 sha: 1a462f5a01bb9d199f636990f8196c09a454a006 doc_id: 991451 cord_uid: w7d37nu9 nan Globally, there have been 44 002 003 confirmed cases of COVID-19, including 1 167 988 deaths, reported to the World Health Organization (WHO). 10 To date, there have been 8 683 298 confirmed cases of COVID-19 with 225 073 deaths in the USA. 10 Preclinical and clinical studies consistently report a significant elevation in proinflammatory cytokines in COVID- 19, 9, [11] [12] [13] especially in stages of COVID-19 disease accompanied by acute respiratory distress resulting from 'cytokine storm'. [14] [15] [16] [17] [18] Related to the significant increase in proinflammatory cytokines, symptoms, like those observed in cancer patients with cachexia, have also been observed in conjunction with 13 Symptoms, similar to those observed in CC including sarcopenia, anorexia, unplanned weight loss, fatigue and functional loss, have been observed to be accelerated in patient populations at all stages of patients diagnosed with COVID-19. [11] [12] [13] However, the data regarding the prevalence and prognosis of COVID-10-related cachexia accounting for age, stage at presentation, and other co-morbidities have not been comprehensively evaluated. Additionally, with factors such as anorexia, age at presentation, immobility due to mechanical ventilation or oxygen supplementation, preexisting nutritional deficiencies and decreased physical activity due to isolation, fatigue, hypoxemia, sarcopenia, and weight loss has been observed to be accelerated in patient populations with COVID-19. [11] [12] [13] It is unknown if COVID-19-related sarcopenia and cachexia persists post recovery and if it is reversible. A recent report of results of a preclinical study has shown that suppression of host inflammatory response in early stages of COVID-19 with interventions can reverse cachexia and increase survival. 12 Based on this early and evolving observations, it can be hypothesized that if early COVID-19-related cachexia mimics early stages of cancer-related cachexia, cachexia in these patient populations can be targeted early and potentially reversed, thus reducing mortality in these patient populations. In addition, cancer patients presenting with COVID-19 may be at exceptional risk of sarcopenia and cachexia. The goal of the current editorial is to compare the mechanisms and clinical biomarkers and discus the potential targets for clinical management of this phenomena in both COVID-19 and cancer-related sarcopenia and cachexia. Our understanding of these mechanisms may potentially identify targets and inform management of early stages of both cancer-related and COVID-19-related cancer cachexia. In addition to the diagnosis of cancer, CC is characterized by unplanned weight loss including loss of both skeletal and visceral muscles and fat stores, manifesting in the cardinal features of emaciation, anorexia, hypo albuminuria, myalgia, weakness affecting functional status, hypo albuminuria, significant increase in proinflammatory cytokines, dysfunction of the metabolic processes, and compromised quality of life. 1, 3, [19] [20] [21] [22] [23] [24] [25] [26] Similarly, coronavirus disease (COVID-19) is characterized by a pneumonic process of varying degree depending on the stage at diagnosis, significant increase in proinflammatory cytokines (cytokine storm), 14 anorexia, dysgeusia, anosmia, unplanned weight loss, sarcopenia, myalgia, hypo albuminuria, increased C-reactive proteins, ferratin and proinflammatory cytokines-TNF-alpha, Il-1 and Il-6, 14, 15, 27 which are symptoms similar to cancer cachexia. Inflammatory organ injury has been reported in severe cases. 16 Although not evaluated and characterized in this patient population to date, the prevalence of sarcopenia and cachexia has been reported in this population at all stages with COVID-19, underscoring the need to understand the pathogenesis of COVID-19-related cachexia based on the similarities to CC. Data from both experimental and clinical studies have demonstrated that CC is mediated or modulated by an interplay of a highly complex and multiple biologic pathways. Angiotensin I and angiotensin II levels (Ang II) are increased in patients with CC, 17 leading to elevated levels of proinflammatory cytokines such as TNFα, IL-1, and IL-6. 17, 18, 26, [28] [29] [30] [31] [32] [33] Being produced by both tumour and host, these pro-inflammatory cytokines have frequently been suggested as possible mediators in cachexia. 32, 33 It has been hypothesized that the cytokines that are important in the initiation of the acute phase response (APR) contribute to the genesis of CC. 26, 31 Significant increases in TNF-α have been observed specifically in cachectic patients. 32 TNF-α has been demonstrated to produce direct catabolism of skeletal muscle, increases in protein degradation in conjunction with depression of protein synthesis and catabolism of adipose tissue leading to induction of muscle atrophy. Studies have shown that these changes in protein degradation occurs via the ubiquitin-proteasome pathway, with the formation of reactive oxygen species leading to activation of NF-κB. 34, 35 NF-κB, a critical regulator protein degradation and skeletal muscle proteasome expression, has been shown to be up-regulated in CC. 8, [34] [35] [36] [37] [38] [39] [40] [41] [42] This up-regulation of NF-κB has been shown to increase the rate of myosin heavy chain and telethonin degradation, compromising sarcomere integrity. 43 Sarcopenia in CC is the thus a result of imbalance between protein synthesis and degradation. 44 The Coronovirus-2 spike protein uses angiostensin converter enzyme 2 (ACE2) receptor, that are ubiquitously present in all cells, known to bind to cells resulting in fusion of the viral envelope to fuse with cell membrane, permitting the viral genetic material to enter the cells, contributing to cellular damage at the organ level. 45 Additionally, ACE2 is present in ample quantities in the epithelia of the human lung, small intestine, arterial and venous endothelial cells and arterial smooth muscle cells in all organs studied, providing the first clues in our understanding of the pervasive pathogenesis of the main SARS disease. 46 ACE2 is present in muscle tissue which may explain in part the effect of the virus in sarcopenia. Angiotensin I and angiotensin II levels i (Ang II) have been shown to increase protein breakdown, lower muscle regeneration, and increase apoptosis in muscle tissue. 47, 48 Similar to patients with CC, Ang II are increased in patients with COVID-19 17 and act as an inflammatory mediator leading to elevated levels of proinflammatory cytokines such as TNF-α, Il-1, I1-6, 14,15 through a variety of mechanisms including increasing reactive oxygen species and NF-κB. 49 Thus, there are several similarities in the pathogenesis of both CC and COVID-related cachexia. Patients with a diagnosis of cancer and COVID-19 are at exceptional risk for sarcopenia and cachexia. Advanced cachexia is refractory and has a high mortality rate. Cachexia and sarcopenia continue to impact mortality in cancer and potentially in COVID-19. In patients with early stage disease, sarcopenia and cachexia may impact function, prognosis, and quality of life in patients with cancer and COVID-19. Several studies, including our own, suggest that maintenance of lean body mass including myofibrillar proteins are difficult to achieve in CC, unless we have a clear understanding of the underlying aetiology that can be targeted and reversed/ corrected. 1, 2, 26, 31, 50, 51 Research to understand the pathogenesis, incidence, course, and prognosis of various stages of presentation of disease for both CC and COVID-19-related cachexia and strategies to mitigate the immune response and deliver improved outcomes is much needed. Our current knowledge and evolving evidence from the fields of oncology and COVID-19 may inform management of cachexia in both diseases. The use of dexamethasone in patients diagnosed with COVID-19 and receiving either mechanical ventilation or oxygen alone demonstrated a lower 28-day mortality compared with those patients who did not receive any form of respiratory support. 16 Early evidence including preclinical studies have shown promise with IL-1, IL-6 receptor antagonists to treat COVID-related increase in proinflammatory cytokines. It can be hypothesized that multimodal approaches in early stages of this disease may offer promise and can include (i) early identification of reversible (Stage I) stage of sarcopenia and cachexia, (ii) therapeutic agents to lower viral load (COVID-19)/appropriate treatment to reduce tumour burden (cancer), (iii) timely evaluation of intervention with targeted agents to reduce proinflammatory cytokine levels (dexamethasone, IL-1, IL-6 receptor antagonists), [14] [15] [16] [17] [18] (iv) addition of appetite stimulants to treat anorexia (v) in combination with a nutritionally enriched diets with high quality proteins, antioxidant/anti-inflammatory foods, 1,3 and (vi) incorporating proactive respiratory and physical rehabilitation interventions to improve pulmonary status and muscle mass towards preventing sarcopenia and improving physical function. Effectiveness and safety of these approaches can be evaluated using established as well as recently identified novel biomarkers relevant to the mechanistic pathways. Finding from these studies promise to inform management of CC, COVID-19-related cancer cachexia as well as cachexia in cancer patients with COVID-19. Nutritional Management of Cancer Treatment Effects Cancer-associated cachexia Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment The lethal phenotype of cancer: the molecular basis of death due to malignancy European Palliative Care Research Collaborative. Evolving classification systems for CC: ready for clinical practice? Defining and classifying CC: a proposal by SCRINIO Working Group The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-esophageal cancer Molecular-based therapeutic approaches in treatment of anorexia of aging and CC Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of CC WHO. WHO Coronavirus Disease (COVID-19) Dashboard. Available online at Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies SARS-CoV-2 infection: The role of cytokines in COVID-19 disease COVID-19: a major cause of cachexia and sarcopenia? Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia SARS-CoV-2 infection: The role of cytokines in COVID-19 disease Weight loss in patient with advanced cancer: effects, causes, and potential management Cachexia: a new definition Pharmacological options for advanced cancer patients with loss of appetite and weight Pathophysiology of anorexia Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia Fish oil and treatment of cancer cachexia Nutritional support in multimodal therapy for CC Prognostic effect of weight loss prior to chemotherapy in cancer patients Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomized controlled trial Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment Pro-inflammatory cytokines and oxidative stress/ antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients Cancer cachexia prevention via physical exercise: molecular mechanisms Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor Missing pieces in the NF-kappaB puzzle Barton BE. IL-6-like cytokines and CC: consequences of chronic inflammation The 26S proteasome: a molecular machine designed for controlled proteolysis Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in CC: a randomised double blind trial Adipose triglyceride lipase contributes to cancer-associated cachexia Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients NF-κB signaling in skeletal muscle health and disease NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia Role of the ubiquitin-proteasome pathway in muscle atrophy in cachexia Definition and classification of cancer cachexia: an international consensus Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Covid-19 and the Renin Angiotensin System: Implications for the Older Adults MECHA-NISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES Renin-angiotensin system: an old player with novel functions in skeletal muscle Combining optimal nutrition and exercise in a multimodal approach for patients with active cancer and risk for losing weight: Rationale and practical approach European School of Medical Oncology)Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force